



09-12-07

1623
D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zeldis <i>et al.</i>	Confirmation No.:	7262
Serial No.:	09/853,617	Art Unit:	1623
Filed:	May 14, 2001	Examiner:	Patrick T. Lewis
For:	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER	Attorney Docket No: Docket No:	9516-022-999 501872-999021

SUBMISSION OF REFERENCES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to their response to the Office Action filed October 7, 2007, Applicants note that the references cited in the response may not have been submitted. Therefore, Applicants submit the references for entry into the records and consideration by the Examiner.

Accordingly, enclosed herewith are copies of:


1) *Yamanouchi Pharmaceutical Co., Ltd. v Danbury Pharmacal, Inc.* 231 F.3d 1339, 180 A.L.R. Fed. 743, 56 U.S.P.Q.2d 1641 (2000);

2) *Norra MacReady, Thalidomide Shows Promise in Ovarian Cancer Treatment: Presented at SGO.*, <http://ctep.cancer.gov/resources/gcig/news032406.html>.

No fee is believed due for this submission. If any fees are required for the submission of this paper, or to avoid the abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: September 10, 2007


Hoon Choi Ltd Reg. No. L0209
For Anthony M. Insogna Reg No. 35,203
JONES DAY
12265 El Camino Real
Suite 200
San Diego, California 92130-4096